Omnicell Company Leadership
| OMCL Stock | USD 44.99 0.32 0.71% |
Omnicell employs about 3.7 K people. The company is managed by 18 executives with a total tenure of roughly 56 years, averaging almost 3.0 years of service per executive, having 203.33 employees per reported executive. Inspection of Omnicell's management performance can provide insight into the company performance.
| Randall Lipps Chairman Executive Chairman, CEO and Pres |
| Jorge Taborga President Executive Vice President - Engineering |
Omnicell |
Omnicell Management Team Effectiveness
Omnicell's management efficiency ratios could be used to measure how well Omnicell manages its routine affairs as well as how well it operates its assets and liabilities.Omnicell Workforce Comparison
Omnicell is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 59,660. Omnicell holds roughly 3,660 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03. Omnicell Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Omnicell insiders, such as employees or executives, is commonly permitted as long as it does not rely on Omnicell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Omnicell insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bauer Joanne B over a month ago Disposition of 3318 shares by Bauer Joanne B of Omnicell at 55.0377 subject to Rule 16b-3 | ||
Randall Lipps over a month ago Disposition of 4202 shares by Randall Lipps of Omnicell at 46.01 subject to Rule 16b-3 | ||
Parrish Mark W over a month ago Disposition of 12000 shares by Parrish Mark W of Omnicell at 47.3032 subject to Rule 16b-3 | ||
Nchacha Etta over two months ago Disposition of 593 shares by Nchacha Etta of Omnicell at 45.67 subject to Rule 16b-3 | ||
Nnamdi Njoku over two months ago Acquisition by Nnamdi Njoku of 53520 shares of Omnicell subject to Rule 16b-3 | ||
Randall Lipps over three months ago Disposition of 2500 shares by Randall Lipps of Omnicell subject to Rule 16b-3 | ||
Corey Manley over six months ago Disposition of 221 shares by Corey Manley of Omnicell at 27.91 subject to Rule 16b-3 | ||
Joseph Spears over six months ago Disposition of 117 shares by Joseph Spears of Omnicell at 29.87 subject to Rule 16b-3 |
Omnicell Notable Stakeholders
An Omnicell stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Omnicell often face trade-offs trying to please all of them. Omnicell's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Omnicell's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Randall Lipps | Executive Chairman, CEO and Pres | Profile | |
| Jorge Taborga | Executive Vice President - Engineering | Profile | |
| Scott Seidelmann | Executive Vice President and Chief Commercial Officer | Profile | |
| Peter Kuipers | CFO, Executive Vice President | Profile | |
| Nchacha Etta | Executive CFO | Profile | |
| Nnamdi Njoku | Executive COO | Profile | |
| Brian Nutt | Chief VP | Profile | |
| Joseph Spears | Principal Chief Accounting Officer | Profile | |
| Kathleen Nemeth | Senior Relations | Profile | |
| Vicki MacDevitt | Chief Staff | Profile | |
| Sara Dalmasso | Senior International | Profile | |
| Minoo Mortazavi | Senior Operations | Profile | |
| Corey Manley | Executive Officer | Profile | |
| David Vanella | Senior Regulatory | Profile | |
| Roxanne Turner | Sr Officer | Profile | |
| Christine Mellon | Chief VP | Profile | |
| Maximo Rocha | Senior Officer | Profile | |
| Giri Chodavarapu | Senior Officer | Profile |
About Omnicell Management Performance
The success or failure of an entity such as Omnicell often depends on how effective the management is. Omnicell management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Omnicell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Omnicell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California. Omnicell operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 4000 people.
Omnicell Workforce Analysis
Traditionally, organizations such as Omnicell use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Omnicell within its industry.Omnicell Manpower Efficiency
Return on Omnicell Manpower
| Revenue Per Employee | 313.4K | |
| Revenue Per Executive | 63.7M | |
| Net Loss Per Employee | 5.6K | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 152.9K | |
| Working Capital Per Executive | 31.1M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.